Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)
Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –
Jazz Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Jazz Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $4.72B, up 13.5% year over year. For fiscal 2025 it was $4.27B, up 4.9% from the year before. Over ten years it grew 12.4% a year on average. The highest annual figure on record is $4.27B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.27B | +4.9% |
| FY2024 | Dec 31, 2024 | $4.07B | +6.1% |
| FY2023 | Dec 31, 2023 | $3.83B | +4.8% |
| FY2022 | Dec 31, 2022 | $3.66B | +18.3% |
| FY2021 | Dec 31, 2021 | $3.09B | +30.9% |
| FY2020 | Dec 31, 2020 | $2.36B | +9.3% |
| FY2019 | Dec 31, 2019 | $2.16B | +14.3% |
| FY2018 | Dec 31, 2018 | $1.89B | +16.8% |
| FY2017 | Dec 31, 2017 | $1.62B | +8.8% |
| FY2016 | Dec 31, 2016 | $1.49B | +12.3% |
| FY2015 | Dec 31, 2015 | $1.32B | +13.0% |
| FY2014 | Dec 31, 2014 | $1.17B | +34.4% |
| FY2013 | Dec 31, 2013 | $872.42M | +48.9% |
| FY2012 | Dec 31, 2012 | $585.98M | +115.2% |
| FY2011 | Dec 31, 2011 | $272.28M | +56.7% |
| FY2010 | Dec 31, 2010 | $173.78M | +35.3% |
| FY2009 | Dec 31, 2009 | $128.45M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.24B | +10.4% |
| Q2 FY2026 | Jun 30, 2026 | $1.21B | +15.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.07B | +19.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.20B | +10.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.13B | +6.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.05B | +2.1% |
| Q1 FY2025 | Mar 31, 2025 | $897.80M | -0.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.09B | +7.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.05B | +8.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.02B | +6.9% |
| Q1 FY2024 | Mar 31, 2024 | $901.98M | +1.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.01B | +4.1% |
| Q3 FY2023 | Sep 30, 2023 | $972.14M | +3.3% |
| Q2 FY2023 | Jun 30, 2023 | $957.32M | +2.6% |
| Q1 FY2023 | Mar 31, 2023 | $892.81M | +9.7% |
| Q4 FY2022 | Dec 31, 2022 | $972.12M | +8.4% |
| Q3 FY2022 | Sep 30, 2022 | $940.65M | +12.2% |
| Q2 FY2022 | Jun 30, 2022 | $932.88M | +24.1% |
| Q1 FY2022 | Mar 31, 2022 | $813.72M | +33.9% |
| Q4 FY2021 | Dec 31, 2021 | $896.73M | +34.7% |
| Q3 FY2021 | Sep 30, 2021 | $838.12M | +39.5% |
| Q2 FY2021 | Jun 30, 2021 | $751.81M | +33.7% |
| Q1 FY2021 | Mar 31, 2021 | $607.58M | +13.6% |
| Q4 FY2020 | Dec 31, 2020 | $665.52M | +14.4% |
| Q3 FY2020 | Sep 30, 2020 | $600.89M | +11.8% |
| Q2 FY2020 | Jun 30, 2020 | $562.44M | +5.3% |
| Q1 FY2020 | Mar 31, 2020 | $534.73M | +5.2% |
| Q4 FY2019 | Dec 31, 2019 | $581.74M | +22.1% |
| Q3 FY2019 | Sep 30, 2019 | $537.70M | +14.6% |
| Q2 FY2019 | Jun 30, 2019 | $534.13M | +6.7% |
| Q1 FY2019 | Mar 31, 2019 | $508.19M | +14.3% |
| Q4 FY2018 | Dec 31, 2018 | $476.46M | +9.2% |
| Q3 FY2018 | Sep 30, 2018 | $469.37M | +14.0% |
| Q2 FY2018 | Jun 30, 2018 | $500.48M | +26.9% |
| Q1 FY2018 | Mar 31, 2018 | $444.61M | +18.2% |
| Q4 FY2017 | Dec 31, 2017 | $436.40M | +10.0% |
| Q3 FY2017 | Sep 30, 2017 | $411.86M | – |
| Q2 FY2017 | Jun 30, 2017 | $394.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $376.05M | – |
| Q4 FY2016 | Dec 31, 2016 | $396.62M | – |
See a number that looks wrong?